Evotec and the Jain Foundation expand collaboration
Start of multiple drug screening programmes
Evotec AG and the Jain Foundation Inc. announced that they have further extended and expanded the collaboration first signed in 2012 and extended last year.
This next phase of collaboration includes the screening of compound libraries in multiple assay formats to further support the Jain Foundation's goals of understanding and curing dysferlinopathies, a group of inherited skeletal muscular dystrophy diseases. This marks a major milestone in the efforts of the Jain Foundation to identify therapeutics which can counteract the phenotypes of dysferlin deficiency.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are delighted to continue our relationship with the Jain Foundation and to be a part of this important step in dysferlin research. The progress to date and initiation of multiple screening programmes is a major accomplishment for both organisations and demonstrates Evotec's growing role in driving innovative and industrialised research in partnership with foundations such as the Jain Foundation working in rare diseases."
Dr Plavi Mittal, President and CEO of Jain Foundation, added: "We are pleased with the progress of our project with Evotec to date, and are excited to move forward to the screening phase of our drug development programme."
No financial details are disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
